Abstract
This report analyzes the worldwide markets for Cardiac Biomarkers in Millions
of US$. The market is analyzed by Location-wise (Clinical Laboratory Testing,
and Point-of-Care Testing) and by Assay type-wise (Acute Myocardial Infarction
(AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and
Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides
separate omprehensive analytics for the US, Europe, and Rest of the World.
Annual forecasts are provided for each region for the period of 2006 through
2015. A five-year historic analysis is also provided for these markets. The
report profiles 78 companies including many key and niche players worldwide
such as Abbott Diagnostics, Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter,
Inc., biomérieux, Inverness Medical Innovations, Inc., LifeSign LLC,
Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Oxis International, Inc.,
Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and
Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived
from primary and secondary research. Company profiles are mostly extracted
from URL research and reported select online sources.
| 
View Cart
